Corbus Pharmaceuticals Files 8-K

Ticker: CRBP · Form: 8-K · Filed: Feb 14, 2025 · CIK: 1595097

Sentiment: neutral

Topics: corporate-disclosure, 8-K

Related Tickers: CRBP

TL;DR

CRBP filed a routine 8-K, confirming its Nasdaq listing and HQ location.

AI Summary

Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on February 14, 2025, reporting its status as a publicly traded company. The filing confirms its principal executive offices are located at 500 River Ridge Drive, Norwood, Massachusetts, 02062, and its common stock trades under the symbol CRBP on The Nasdaq Capital Market.

Why It Matters

This 8-K filing serves as a standard corporate disclosure, confirming basic company information and stock listing details for investors and regulatory bodies.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain new material information that would inherently increase risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report current information about Corbus Pharmaceuticals Holdings, Inc., including its principal executive offices and stock trading details.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on February 14, 2025.

Where are Corbus Pharmaceuticals Holdings, Inc.'s principal executive offices located?

Corbus Pharmaceuticals Holdings, Inc.'s principal executive offices are located at 500 River Ridge Drive, Norwood, Massachusetts, 02062.

What is the trading symbol for Corbus Pharmaceuticals Holdings, Inc.'s common stock?

The trading symbol for Corbus Pharmaceuticals Holdings, Inc.'s common stock is CRBP.

On which exchange is Corbus Pharmaceuticals Holdings, Inc.'s common stock traded?

Corbus Pharmaceuticals Holdings, Inc.'s common stock is traded on The Nasdaq Capital Market.

Filing Stats: 1,136 words · 5 min read · ~4 pages · Grade level 11 · Accepted 2025-02-14 08:05:18

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On February 14, 2025, Corbus Pharmaceuticals Holdings, Inc. (the "Company") issued a press release announcing data from the ongoing Phase 1 dose escalation clinical trial for SYS6002 (CRB-701) conducted by the Company in the United States and the United Kingdom (the "Western study"), that is being presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (the "2025 ASCO GU") on February 14, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The Company also updated its presentation used by management to describe its business. A copy of the presentation is furnished as Exhibit 99.2 and is incorporated herein by reference. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibits 99.1 and 99.2, is being furnished to the Securities and Exchange Commission (the "SEC"), and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On February 14, 2025, the Company announced data from the Western study that is being presented at the 2025 ASCO GU on February 14, 2025. The Western study is being conducted in the United States and United Kingdom and is enrolling patients with metastatic urothelial cancer (mUC) and other solid tumors associated with Nectin-4 expression. These included several tumor types not previously explored in the corresponding Phase 1 dose escalation study being conducted in China (the "China study") by the Company's development partner, CSPC Pharmaceutical Group ("CSPC"). The China study enrolled patients with mUC and other solid tumors. Unlike the China study, participants in the Western study were recruited regardless of their individual Nectin-4 levels. The Western study opened for enrollment in April 2024 and the enrollment for dose escalation was completed in October 2024. A December 2024 data cut is being presented (n=38) of whom 26 participants were evaluable for efficacy. The Western study enrolled into the top four dose cohorts used in China (1.8, 2.7, 3.6 and 4.5 mg/kg) and adopted the same Q3W regimen. Safety: No dose limiting toxicities were encountered during the dose escalation phase of both studies. CRB-701 was well tolerated with majority of treatment emergent adverse events being grade 1 or 2 in both studies. Notably few cases of peripheral neuropathy or skin rash have been reported to date in either study: o Peripheral neuropathy: Western study (Grade 1-2: 5% (n=2/38), (Grade 3 or above: zero) was comparable to China study (Grade 1: 3% (n=1/37), Grade 2 or above: zero). The combined peripheral neuropathy rate for both studies was 4% (n=3/75). o Skin and subcutaneous disorders: 24% (n=9/38) in the Western study compared to 8% (n=3/37) in the China study. The combined rate for both studies was 16% (12/75) across all dose groups. Ocular adverse events: implementation of a proactive, preventative ocular toxicity protoco

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated February 14, 2025 99.2 Investor Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Corbus Pharmaceuticals Holdings, Inc. Date: February 14, 2025 By: /s/ Yuval Cohen Name: Yuval Cohen Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing